Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
TM Ganten, R Koschny, TL Haas, J Sykora… - Hepatology, 2005 - journals.lww.com
TRAIL exhibits potent anti-tumor activity on systemic administration in mice. Because of its
provenin vivoefficacy, TRAIL may serve as a novel anti-neoplastic drug. However,
approximately half of the tumor cell lines tested so far are TRAIL resistant, and potential toxic
side effects of certain recombinant forms of TRAIL on human hepatocytes have been
described. Pretreatment with the proteasome inhibitor MG132 and PS-341 rendered TRAIL-
resistant hepatocellular carcinoma (HCC) cell lines but not primary human hepatocytes …
provenin vivoefficacy, TRAIL may serve as a novel anti-neoplastic drug. However,
approximately half of the tumor cell lines tested so far are TRAIL resistant, and potential toxic
side effects of certain recombinant forms of TRAIL on human hepatocytes have been
described. Pretreatment with the proteasome inhibitor MG132 and PS-341 rendered TRAIL-
resistant hepatocellular carcinoma (HCC) cell lines but not primary human hepatocytes …